Aurecon

Aurecon is providing structural, façade, electrical, information and communications technology and dry fire engineering services for the Translational Research Institute (TRI), located at the Princess Alexandra Hospital in Brisbane, Australia.

TRI will be an Australian first and will see Australia play a leading role in international efforts to address infectious disease, cancer and diabetes. As one of the southern hemisphere's largest facilities of its kind, TRI will be one of only a few places worldwide where new biopharmaceuticals and treatments can be researched, discovered, produced, clinically tested, and manufactured in one location. 

Due for completion in 2012, the TRI building will house 700 researchers and include physical containment level 2 (PC 2) and 3 (PC 3) laboratories, an animal house, clean rooms, a Cell Therapies facility, staff support spaces, a large lecture theatre and advanced education facilities. The associated and adjacent biopharmaceuticals facility will house a pilot drug manufacturing facility to bring discoveries to pilot commercialisation.

The electrical and ICT component of the project includes a significant Tier 2.5 tertiary data centre, F/UTP Category 6A structured cabling infrastructure, two in-building 11kV/415V substations, 3.2MW of 11kV standby generation, 70kW of photovoltaics and intelligent energy management for improved efficiency.

TRI is a joint venture involving the University of Queensland, Queensland University of Technology, Princess Alexandra Hospital, Mater Medical Research Institute and the Queensland Government and is supported by grants from the Australian Government, Queensland Government and Atlantic Philanthropies.

For more information, please visit the Translational Research Institute website.